Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Does previous SARS-CoV-2 infection affect vaccine-induced immunity?

Researchers report the binding and pseudo-neutralizing antibody titers elicited after patients had received either the Pfizer-BioNTech or AstraZeneca vaccines.

24 Oct 2021

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.

22 Oct 2021

SARS-CoV-2 anti-nucleocapsid antibodies reduce risk of reinfection for at least eight months

A new study concludes that at least with predominantly wild-type variants, the risk of reinfection with the virus among unvaccinated people is reduced by 80% or more.

22 Oct 2021

Study shows immune profile heterogeneity amongst healthy adults

Researchers opted to use single-cell RNA-seq to observe single cells in detail as they encounter a specific antigen.

22 Oct 2021

Immunogenicity and efficacy of adjuvanted SARS-CoV-2 beta variant subunit booster in rhesus macaques

Scientists studied the efficacy of an intranasal booster composed of beta variant-spike protein S1 with IL-15 and TLR agonists in macaques that were previously immunized.

22 Oct 2021

Development of a safe and effective COVID-19 nanoparticle vaccine

Researchers from ReVacc scientific have attempted to demonstrate the effectiveness of a new vaccine, REVC-128, two weeks post-administration.

22 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

Boosting nonhuman primates with Moderna vaccine increases neutralizing antibody responses

Boosting nonhuman primates with the Moderna vaccine (mRNA-1273) six months after their primary vaccine series increased neutralizing activity against viral variants of concern, a new study shows.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

21 Oct 2021

First investigational xenotransplantation marks a major step towards adequate organ supply

The first investigational transplant of a genetically engineered, nonhuman kidney to a human body was recently completed at NYU Langone Health—marking a major step forward in potentially utilizing an alternative supply of organs for people facing life-threatening disease.

21 Oct 2021

Booster dose of COVID-19 vaccine significantly increases neutralizing antibodies in rhesus macaques

A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues.

21 Oct 2021

Antibody News and Research

Further Reading

Does previous SARS-CoV-2 infection affect vaccine-induced immunity?

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

SARS-CoV-2 anti-nucleocapsid antibodies reduce risk of reinfection for at least eight months

Study shows immune profile heterogeneity amongst healthy adults

Immunogenicity and efficacy of adjuvanted SARS-CoV-2 beta variant subunit booster in rhesus macaques

Development of a safe and effective COVID-19 nanoparticle vaccine

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Boosting nonhuman primates with Moderna vaccine increases neutralizing antibody responses

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

First investigational xenotransplantation marks a major step towards adequate organ supply

Booster dose of COVID-19 vaccine significantly increases neutralizing antibodies in rhesus macaques

EKF Diagnostics to showcase at Medica 2021 STAT-Site® WB β-ketone and glucose handheld analyzer live & in person

Development of a plant-based platform for the production of SARS-CoV-2 antigen

Immune responses to SARS-CoV-2 infection and vaccination in patients with multiple sclerosis

Researchers develop a new method to remove old cells from tissues to slow down aging

Children show lower seroconversion rates than adults with mild COVID-19

New research on phagocytosis and SARS-CoV-2's spike protein

The neutralization potential of nanobodies against SARS-CoV-2

New oligomer shows promising anti-SARS-CoV-2 properties

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo